I mentioned yesterday that Merck had dropped its annual drug-price transparency report, warning that Merck’s numbers probably shouldn’t be extrapolated to the broader industry. After all, most companies don’t have
Confession: after a week of what feels like daily bombshells, I fear my brain is full. There’s plenty to talk about today that has gone under-recognized or under-analyzed, but there’s
It’s kind of a slow day today, which has me thinking ahead to the J.P. Morgan Health Care conference in January. My thoughts are swirling around a couple of things: